250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O’Connor(St. Michael's Hospital), Timon Bogumil(Bayer (United States)), Maria Groth(Bayer (Germany)), Douglas S. Goodin(San Francisco VA Medical Center), Gıancarlo Comı(Vita-Salute San Raffaele University), Francis Boateng(Bayer (United States)), Ludwig Kappos(Novartis (Switzerland)), Volker Knappertz(Tris Pharma (United States)), Christoph Pohl, Christian Kraus(Bayer (Germany)), Rupert Sandbrink(Io Therapeutics (United States)), Douglas Jeffery(University of New Mexico), Barry G.W. Arnason, Hans-Peter Hartung(The University of Sydney), Massimo Filippi(Vita-Salute San Raffaele University), Stuart D. Cook(Rutgers, The State University of New Jersey), В. Л. Филиппов(Bayer (Germany))
Cited by 403
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k